Projekt
A double-blind, randomized, placebo-controlled Phase III study to assess the efficacy of recMAGE-A3 + AS15 ASCI as adjuvant therapy in patients with MAGE-A3 positive resected stage III melanoma; Short Title: GSK 2132231A Antigen-Specific Cancer Immunotherapeutic as adjuvant therapy iin patients with resexted melanoma
Automatisch geschlossen · 2010 bis 2015
Heinzerling Lucie
Art
Grundlagenforschung
Reichweite
Monozentrisch am KSSG
Bereiche
Status
Automatisch geschlossen
Start
2010
Ende
2015
Finanzierungsart
Industrie
Kurzbeschreibung/Zielsetzung
A double-blind, randomized, placebo-controlled Phase III study to assess the efficacy of recMAGE-A3 + AS15 ASCI as adjuvant therapy in patients with MAGE-A3 positive resected stage III melanoma; Short Title: GSK 2132231A Antigen-Specific Cancer Immunotherapeutic as adjuvant therapy iin patients with resexted melanoma